c-MET CDx for NSCLC

c-MET companion diagnostic immunohistochemistry (IHC) assay

Accurate and timely biomarker testing is critical in lung cancer, where targeted therapies can meaningfully change the course of a patient’s treatment. The c-MET CDx for NSCLC assay detects c-Met protein overexpression, a biomarker observed in up to 50% of patients with advanced NSCLC.¹ It is designed to help identify patients who may be eligible for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), which was recently approved by the U.S. Food and Drug Administration (FDA).*

Key features of NeoGenomics’ assay include:

Companion Diagnostic Indication: Developed in accordance with FDA guidance and validated for use with MET-targeted therapies.
Fast Turnaround: Delivers results within 48 hours to enable timely, informed clinical decisions.
Validated Performance: Designed for use with tumor tissue samples to detect MET protein overexpression.
Integrated NSCLC Offering: Complements NeoGenomics’ broader PanTracer™ portfolio, including genomic and immuno-oncology markers.

The c-MET CDx for NSCLC assay is now available as part of NeoGenomics’ comprehensive NSCLC testing portfolio. Its addition supports the growing use of MET-directed therapies and reflects ongoing efforts to align diagnostic services with emerging standards in precision cancer care.

For more information or to order the test, visit our test menu page.

*EMRELIS™ (telisotuzumab vedotin-tllv) was approved by the U.S. FDA on May 14, 2025, for adults with previously treated advanced NSCLC with high c-MET protein overexpression.

References

Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023;41(5):1105-1115. doi:10.1200/JCO.22.00739